Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients

Abstract

Rationale

Atypical antipsychotic drugs are classically associated with lower propensity to extrapyramidal symptoms (EPS) and hyperprolactinemia than typical antipsychotic drugs. It has not been clarified why some atypical antipsychotic drugs, such as amisulpride, induce prolactin plasma concentration (PRL) elevation, but little EPS. Previous studies have found an association between striatal D2/D3 receptor occupancy and PRL in typical antipsychotic treated patients suggesting that PRL is a marker of central D2/D3 receptors blockade.

Objective

We have evaluated the relationship between PRL and central (striatum, temporal cortex and thalamus) D2/D3 receptor occupancy in amisulpride treated schizophrenic patients.

Methods

Single photon emission tomography (SPET) and [123I]-epidepride were used to determine D2/D3 receptor occupancy in eight amisulpride treated patients. PRL was measured concurrently with the scans.

Results

The mean PRL was 1166 (range 499–1892 mIU/l) for a mean amisulpride dose of 406 mg/day (range 150–600 mg/day). Amisulpride plasma concentration and central D2/D3 receptor occupancy were positively correlated (r=0.83–0.89, df=4, P<0.05). No significant correlations were observed between PRL and amisulpride (daily dose or plasma concentration, P>0.05), or between PRL and central D2/D3 receptor occupancy (P>0.05).

Conclusions

Our findings show that amisulpride-induced hyperprolactinemia is uncoupled from central D2/D3 receptor occupancy. Amisulpride has poor blood–brain barrier penetration and reaches much higher concentration at the pituitary, which is outside the blood–brain barrier. Higher D2/D3 receptor occupancy at the pituitary gland than at central regions is a possible explanation for amisulpride PRL elevation with low EPS. Further studies evaluating pituitary D2/D3 receptor occupancy in vivo are necessary to confirm this hypothesis.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201–208

    Article  CAS  Google Scholar 

  2. Alcohol Drug Abuse, and Mental Health Administration (1974) Abnormal involuntary movement scale (AIMS). Department of Health, Education and Welfare, Washington D.C.

  3. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676

    CAS  PubMed  Google Scholar 

  4. Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS (2003a) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413–1420

    Article  PubMed  Google Scholar 

  5. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003b) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23:5–14

    Article  CAS  PubMed  Google Scholar 

  6. Brown WA, Laughren TP (1981) Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res 5:317–322

    Article  CAS  PubMed  Google Scholar 

  7. Erlandsson K, Bressan RA, Mulligan RS, Ell PJ, Cunningham VJ, Pilowsky LS (2003) Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings. Neuroimage 19:1205–1214

    Article  PubMed  Google Scholar 

  8. Flores CM, Hulihan-Giblin BA, Hornby PJ, Lumpkin MD, Kellar KJ (1992) Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin. Neuroendocrinology 55:519–528

    CAS  PubMed  Google Scholar 

  9. Folstein M, Folstein F, McHugh P (1975) Mini mental state—a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12:189–198

    CAS  PubMed  Google Scholar 

  10. Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A, Halpern FS (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35:108–116

    CAS  PubMed  Google Scholar 

  11. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, Hiemke C, Benkert O (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45:89–97

    PubMed  Google Scholar 

  12. Igarashi Y, Higuchi T, Toyoshima R, Noguchi T, Moroji T (1985) Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Adv Biochem Psychopharmacol 40:95–98

    CAS  PubMed  Google Scholar 

  13. Invitti C, Danesi L, Dubini A, Cavagnini F (1998) Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients. Acta Endocrinol 118:381–388

    Google Scholar 

  14. Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacology 35:1503–1519

    Google Scholar 

  15. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514–520

    CAS  PubMed  Google Scholar 

  16. Kapur S, Langlois X, Vinken P, Megens AA, de Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129–1134

    Article  CAS  PubMed  Google Scholar 

  17. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276

    CAS  Google Scholar 

  18. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19:603–606

    CAS  PubMed  Google Scholar 

  19. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158

    Article  CAS  PubMed  Google Scholar 

  20. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RSJ (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16:42–52

    CAS  PubMed  Google Scholar 

  21. Laughren TP, Brown WA, Williams BW (1979) Serum prolactin and clinical state during neuroleptic treatment and withdrawal. Am J Psychiatry 136:108–110

    CAS  PubMed  Google Scholar 

  22. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180–190

    Article  PubMed  Google Scholar 

  23. Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loc’h C, Maziere B (1996) In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124:154–158

    CAS  PubMed  Google Scholar 

  24. Melkersson KI, Hulting AL, Rane AJ (2001) Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51:317–324

    Article  CAS  PubMed  Google Scholar 

  25. Meltzer HY (1985) Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol 40:59–68

    CAS  PubMed  Google Scholar 

  26. Meltzer HY, Fang VS (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33:279–286

    CAS  PubMed  Google Scholar 

  27. Mizuchi A, Kitagawa N, Miyachi Y (1983) Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacology 81:195–198

    CAS  PubMed  Google Scholar 

  28. Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L (1998) Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 96:223–226

    Google Scholar 

  29. Naber D, Fischer H, Ackenheil M (1979) Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance? Commun Psychopharmacol 3:59–65

    CAS  PubMed  Google Scholar 

  30. Nördstrom AL, Farde L (1998) Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 18:305–310

    PubMed  Google Scholar 

  31. Nördstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C et al. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227–235

    PubMed  Google Scholar 

  32. Overall J, Gorham D (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812

    Google Scholar 

  33. Protais P, Hermier C, Costentin J (1985) The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration. Neuropharmacology 24:861–867

    Article  CAS  PubMed  Google Scholar 

  34. Rao ML, Brown WA (1987) Stability of serum neuroleptic and prolactin concentrations during short-term and long-term treatment of schizophrenic patients. Psychopharmacology 93:237–242

    Google Scholar 

  35. Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5:273–282

    Google Scholar 

  36. Schlosser R, Grunder G, Anghelescu I, Hillert A, Ewald-Grunder S, Hiemke C et al. (2002) Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 46:33–40

    Article  CAS  PubMed  Google Scholar 

  37. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11–19

    CAS  Google Scholar 

  38. Talairach J, Tourneaux P (1988) Co-planar stereotactic atlas of the human brain. Thieme, New York

  39. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc’h C, Maziere B, Paillere-Martinot ML (2001) In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21:207–214

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

R.A. Bressan was supported by a charitable educational grant from Sanofi Synthelabo during the data collection. K. Erlandsson is supported on a UK MRC Senior clinical research fellowship. L.S. Pilowsky is a UK Medical Research Council (MRC) Senior Clinical Research Fellow.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Rodrigo A. Bressan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bressan, R.A., Erlandsson, K., Spencer, E.P. et al. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology 175, 367–373 (2004). https://doi.org/10.1007/s00213-004-1826-6

Download citation

Keywords

  • Prolactin
  • Antipsychotic agents
  • Atypical antipsychotic
  • Neuroleptic
  • Dopamine receptor
  • D2-dopamine
  • Schizophrenia
  • SPECT
  • [123I]-epidepride
  • Amisulpride
  • Photon emission tomography